Capital World Investors filed a Schedule 13G with the SEC on November 11, 2026, disclosing beneficial ownership of 8,255,584 shares of Definium Therapeutics, Inc. common stock, representing 6.1% of the class, as of a triggering event dated September 30, 2026.
Key Highlights
- Beneficial ownership: Capital World Investors reported aggregate beneficial ownership of 8,255,584 shares of Definium Therapeutics, Inc. common stock.
- Percent of class: The 8,255,584 shares represent 6.1% of the 134,366,950 shares believed to be outstanding, according to the filing.
- Sole voting and dispositive power: Capital World Investors holds sole voting power and sole dispositive power over all 8,255,584 shares, with no shared voting or dispositive power reported.
- Triggering date: The date of event requiring the filing is stated as September 30, 2026.
- Third-party interest: The filing identifies SMALLCAP World Fund, Inc. as a person known to have the right to receive or direct the receipt of dividends or proceeds from the sale of the securities.
- Filer classification: Capital World Investors is classified as an investment adviser (Type: IA), organized in Delaware, with its principal office at 333 South Hope Street, 55th Floor, Los Angeles, California 90071.
Capital World Investors Crosses 5% Threshold in Definium Therapeutics Common Stock
According to the Schedule 13G filing, Capital World Investors ("CWI") is described as "a division of Capital Research and Management Company ('CRMC'), as well as its investment management subsidiaries and affiliates," including Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited. The filing states that CWI's divisions of each of these investment management entities "collectively provide investment management services under the name 'Capital World Investors.'"
The filing reports that CWI is "deemed to be the beneficial owner of 8,255,584 shares or 6.1% of the 134,366,950 shares believed to be outstanding." All 8,255,584 shares carry sole voting power and sole dispositive power held by Capital World Investors, with zero shares subject to shared voting or shared dispositive power. The issuer, Definium Therapeutics, Inc., is listed with a principal executive office address of One World Trade Center, Suite 8500, New York, NY 1007, and its common stock carries CUSIP number 24477V105.
The filing was signed by Timothy J. Moon, identified as Vice President and Senior Counsel, Capital Research and Management Company, on November 11, 2026. The certification included in the filing states that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."
What Was Disclosed
Capital World Investors filed a Schedule 13G disclosing a 6.1% beneficial ownership position, equating to 8,255,584 shares, in Definium Therapeutics, Inc. common stock, based on a September 30, 2026 triggering event, with SMALLCAP World Fund, Inc. identified as having an interest in the securities.



Please wait processing your request...